((自动化翻译由路透提供，请见免责声明 )) (在第2、3、4和5段增加了试验的细节，在第6段增加了疾病的背景资料)
路透9月12日 - Fulcrum Therapeutics 周四表示，其治疗一种肌肉疾病的实验性药物未能在一项后期研究中达到主要目标，导致该公司股价在收盘前下跌近70%。
该公司正在对其药物losmapimod进行测试，260名面胛肱肌营养不良症患者(FSHD) 接受了48周的治疗或安慰剂治疗。
在治疗期结束时，接受该药物治疗的患者在肩部和手臂近端活动度方面没有显示出改善，而肩部和手臂近端活动度正是该研究的主要目标。该研究的次要目标也没有达到统计学意义。
鉴于上述结果，该公司表示计划暂停losmapimod在FSHD患者中的试验。
FSHD是一种遗传性疾病，会导致面部、肩胛骨和上臂肌肉无力和萎缩。据肌肉萎缩症协会估计，该病的发病率约为每10万人中有4例。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.